Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This halts the replication of rapidly dividing cells, such as cancer cells and activated immune cells, thereby reducing tumor growth and dampening autoimmune inflammation.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Healthcare providers determine the appropriate amount and frequency, and patients should follow the prescription exactly as written.

Methotrexate is classified as Pregnancy Category X because it can cause severe fetal harm and birth defects. It is contraindicated in pregnancy and women of child‑bearing potential must use effective contraception. Breastfeeding is also not recommended while receiving methotrexate.

To request Metoject, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Metoject (methotrexate) is a cornerstone antimetabolite with a broad therapeutic range, whereas alternatives like azathioprine or cyclophosphamide have different toxicity profiles and mechanisms. Methotrexate offers oral and injectable options, well‑studied efficacy in both oncology and autoimmune diseases, but requires careful monitoring for hepatic and hematologic effects.

Metoject should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability. Do not freeze the medication.

Metoject is supplied for subcutaneous injection. A healthcare professional prepares the dose using aseptic technique and administers it into the subcutaneous tissue, typically in the abdomen or thigh. Patients should be instructed on proper injection technique and site rotation to minimize local reactions.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, life‑threatening infections, pulmonary toxicity such as interstitial pneumonitis, significant liver injury, and renal failure. Prompt recognition of symptoms and regular laboratory monitoring are essential to mitigate these dangers.

Metoject is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver disease, uncontrolled infections, and those with severely impaired renal function. It should also be avoided in patients receiving certain interacting medications unless closely supervised by a physician.